A hemostatic composition of matter includes a coherent blend of collagen fibrils combined with starch particles as a fluffy mass with hemostatic properties better than collagen fibrils alone or starch particles alone, the composition exhibiting a level of coherence wherein the composition can be lifted, without crushing fibrils, without loss of more than 5% of 10% of a total weight of starch particles from the composition. Sheets with less than 10% by weight of additional binder are also disclosed.

Disclosed herein are engineered bacteria that manufacture biofilms from bacterial amyloid structures. These biofilms and biofilm matrices are capable of generating fibrous proteinaceous networks and being used as 3D-printing inks.

The present invention provides tissue sealant compositions and vasculature closure devices useful for the optical detection of tissue seal and/or clot formation. Compositions and devices of the present invention comprise optical dyes which undergo an observable change as the compositions and/or devices are incorporated into a tissue seal and/or clot, for example a change in fluorescence quantum yield and/or a change in visual color including a change in emission and/or absorption wavelength. Tissue sealants and vasculature closure devices of the present invention are useful for visualizing seal and/or clot formation, for example, during or after surgical procedures, after catheter removal, etc. The present invention further provides methods for formation and optical detection of tissue seals or vasculature puncture closures as well as medical kits useful for the formation and optical detection of tissue seals or vasculature puncture closures.

The present invention provides an improved tissue adhesive to repair defects in soft tissue. Following ASTM standard tests, crosslinked methacryloyl-substituted gelatin hydrogels of the present invention (GelSEAL) were shown to exhibit adhesive properties, i.e. wound closure strength, shear resistance and burst pressure, that were superior to clinically used fibrin- and poly(ethylene glycol)-based glues. Chronic in vivo experiments in rats proved GelSEAL to effectively seal large lung leakages without additional sutures or staples, presenting improved performance as compared to fibrin and poly(ethylene glycol) glues. Furthermore, subcutaneous implantation in rats revealed high biocompatibility of GelSEAL as evidenced by low inflammatory host response. Advantageously, the tissue adhesives of the present invention are low cost and easy to produce, making them a promising substance to be used as a sealant for fluid leakages in soft tissue, as well as an easily tunable platform to further optimize the adhesive characteristics.

A hemostatic device comprising a biomaterial matrix and a polymeric material prepared by combining the polymeric material with a solvent, applying the combination to the biomaterial, removing the solvent, and retaining an effective layer of the polymeric material to the biomaterial to enhance the performance of the hemostatic device in the treatment of wounds.

Disclosed are terpolymer adhesives comprising three different repeating domains: a catechol containing domain, a zwitterionic domain, and a crosslinking domain. In specific examples, the polymer can contain a 3,4-dihydroxy-L-phenylalanine (DOPA) segment which contains a catechol group, a poly(sulfobetaine methacrylate) (polySBMA), and poly(ethylene glycol) dimethacrylate (PEGDMA) for light crosslinking. Alternatively, a photocleavable nitrobenzyloxycarbonyl containing crosslinker can be used. The disclosed polymers can be used as biomedical adhesives, such as to prevent leakage from the sutured intestinal tissue.

Disclosed are terpolymer adhesives comprising three different repeating domains: a catechol containing domain, a zwitterionic domain, and a crosslinking domain. In specific examples, the polymer can contain a 3,4-dihydroxy-L-phenylalanine (DOPA) segment which contains a catechol group, a poly(sulfobetaine methacrylate) (polySBMA), and poly(ethylene glycol) dimethacrylate (PEGDMA) for light crosslinking. Alternatively, a photocleavable nitrobenzyloxycarbonyl containing crosslinker can be used. The disclosed polymers can be used as biomedical adhesives, such as to prevent leakage from the sutured intestinal tissue.

A blood product (10), a method for preparing the blood product, a blood product obtainable by the method and a blood product preparing container means. The blood product comprises components from whole blood, especially fibrin, thrombocytes and leukocytes. The blood product (10) comprises a first layer (21), a second layer (22) and a third layer (23). The second layer (22) is adjacent to the first layer (21) and the third layer (23). The first layer (21) defines a first outer surface (24) of the blood product (10) and the third layer (23) defining a second outer surface (25) of the blood product (10). The first layer (21) comprises a majority of fibrin, the second layer (22) comprises a majority of thrombocytes and the third layer (23) comprises a majority of leukocytes.

Methods are provided for making freeze dried hydrogel and structures therefrom that may be introduced into a patient's body for medical applications. Precursor components are combined to initiate crosslinking. The combined precursor components are placed in a chilled tray, and allowed to crosslink to a desired level of complete crosslinking before and/or after being placed onto the tray. The partially crosslinked hydrogel is frozen and freeze dried. After freeze drying, the hydrogel is conditioned to substantially complete crosslinking, and formed into one or more structures, e.g., plugs, hemostatic, or other medical devices. For example, the hydrogel may be cut, machined, rolled, folded, compressed, and/or cored into that may be loaded into delivery devices that may be introduced into a body to implant or otherwise deliver the structures into the body, e.g., to seal a puncture or other passage through tissue.

Methods are provided for making freeze dried hydrogel and structures therefrom that may be introduced into a patient's body for medical applications. Precursor components are combined to initiate crosslinking. The combined precursor components are placed in a chilled tray, and allowed to crosslink to a desired level of complete crosslinking before and/or after being placed onto the tray. The partially crosslinked hydrogel is frozen and freeze dried. After freeze drying, the hydrogel is conditioned to substantially complete crosslinking, and formed into one or more structures, e.g., plugs, hemostatic, or other medical devices. For example, the hydrogel may be cut, machined, rolled, folded, compressed, and/or cored into that may be loaded into delivery devices that may be introduced into a body to implant or otherwise deliver the structures into the body, e.g., to seal a puncture or other passage through tissue.